TearOptix, a Silicon Valley contact lens innovator focused on next-generation solutions for presbyopia, has secured a strategic round of corporate financing backed by investors with strong expertise in ophthalmology. The funding will support the company’s clinical development program and accelerate plans to bring its proprietary multifocal contact lens technology to market.
Presbyopia, the age-related inability to focus on near objects, affects more than two billion people globally. TearOptix aims to address this widespread condition through its tear and blink-responsive multifocal platform, designed to offer clarity, comfort, and continuous visual performance at all distances. The company stated that the funding validates the promise of its approach, positioning it to pursue regulatory pathways.
TearOptix also introduced its newly created Scientific Advisory Board, a group of prominent global experts in clinical ophthalmology, vision science, and optical engineering. The board will guide product development, clinical strategy, and commercialization efforts. Its members include Dr. Ian Cox, Dr. Jennifer Fogt, Dr. Damien Gatinel, Dr. Richard Lindstrom, Dr. James Wolffsohn, and Dr. Aaron Zimmerman.
The combination of new capital and the formation of the advisory board strengthens TearOptix’s ability to scale its technology as demand for presbyopia solutions grows worldwide. The company said it expects this integrated scientific and clinical leadership to play a central role as it advances toward regulatory review and market introduction.
KEY QUOTES:
“Presbyopia remains a major challenge in contact lens-based vision correction. What excites me about TearOptix’s novel approach is its potential to transform everyday vision for millions of people. Our breakthrough technology, our exceptional team and advisors, and the strategic funding together form a strong foundation for delivering our transformative solution to patients worldwide.”
Vance Thompson, MD, Refractive and Cataract Surgeon, Founder of Vance Thompson Vision, and Co-Founder of TearOptix
“The capital infusion enables us to advance our clinical development and validates our proprietary multifocal lens technology. With the strategic guidance of our Scientific Advisory Board, we are moving rapidly to ensure that our products meet the highest standards of safety and clinical performance, establishing a basis for regulatory clearance.”
“This investment represents a major step forward in our mission to redefine vision correction for presbyopia. It underscores the confidence our investors have in the science behind our technology and the strength of our team. With continued collaboration from our Scientific Advisory Board, we’re accelerating progress toward delivering innovative optical solutions that improve patients’ quality of life.”
Vartan Ghazarossian, Ph.D., Co-Founder and CEO of TearOptix
